Pregabalin + Methylcobalamin belongs to a cyclic GABA analogue category developed by the U.S. Food And Drug Administration and initially approved for treating neuropathic pain.

Pregabalin + Methylcobalamin used to manage neuropathic pain, diabetic neuropathy, postherpetic neuralgia, and other neurological conditions involving nerve pain.

Pregabalin + Methylcobalamin is a prescription medicine available as a tablet and capsule form. Do not crush, chew, or open the medicine. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition. Only stop taking the tablet if your doctor advises you to stop.

The side effects known to occur commonly during the treatment with Pregabalin + Methylcobalamin are dizziness, dry mouth, diarrhea, and weight gain. Some serious side effects also blood clots, heart problems, swelling, and difficulty in concentrating or thinking.

Pregabalin + Methylcobalamin is contraindicated in individuals with known hypersensitivity or allergy to it or its component. Individuals with kidney problems should use this drug with caution. Dose adjustments may be necessary based on the severity of renal impairment to prevent potential adverse effects. If you have severe kidney problems, your doctor must carefully assess the risks and benefits before prescribing this combination.

Pregabalin + Methylcobalamin is unsafe to take during pregnancy as it may affect the fetus's growth, and breastfeeding is not recommended in patients taking this drug because it is unknown whether the medicine passes into the breast milk and harms your baby.

Share your complete medical history with your physician before starting the combination therapy, including any allergies, current medications, and previous medical conditions. Pay attention to how you feel while taking the medications. If you experience any unusual side effects, such as dizziness, drowsiness, nausea, or rash, inform your doctor immediately. Pregabalin + Methylcobalamin can be less effective in elderly patients (65 years and older). Dosage adjustments and cautious monitoring may be necessary in this age group.

1. Strides Shasun Ltd., [Accessed on 20th July 2023], https://www.strides.com/pdf/Branded/africa/renerve_p.pdf
2. Misty D. Smith, Cameron S. Metcalf, and Karen S. Wilcox, Pharmacotherapy of the Epilepsies, Goodman & Gilman's Pharmacological Basis of Therapeutics, 13th Edition, 2018, 303-326.
3. KD Tripathi, Essentials of Medical Pharmacology, Drugs acting on the central nervous system, 7th edition, 2013, 420.

The drug information on this page is not a substitute for medical advice; it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.